Actively Recruiting
Study to Surveil and Track the Outcomes of Chronic Latent EBV Infection Based on Healthy Volunteers Undergoing Routine Inspection
Led by Huazhong University of Science and Technology · Updated on 2021-02-10
10000
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying people who have a high amount of Epstein-Barr virus DNA in their blood but have healthy immune systems. The goal is to understand how this chronic high level of the virus might relate to blood cancers and to explore the genetic reasons why the virus can evade the immune system and potentially lead to tumors. This study focuses on the natural history of long-term latent EBV infection and its possible connection to serious blood diseases. Participants with a high EBV-DNA load in their blood are enrolled and followed over time without any treatment intervention. They are grouped based on their viral load into mild high load and severe high load categories. Follow-up occurs through regular phone calls or face-to-face interviews to monitor their health and any development of blood-related cancers, such as lymphomas and other EBV-associated diseases. During the study, participants undergo periodic assessments to track their condition, including monitoring for hematological malignancies over five years or longer if needed. Researchers collect data through interviews and clinical examinations to understand disease progression and genetic factors involved. The study aims to provide insights into how chronic EBV infection may lead to cancer and immune system escape, with ongoing monitoring to ensure participant safety and data accuracy.
CONDITIONS
Brief Title
Surveillance and Tracking the Outcomes of Chronic Latent EBV Infection
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Immunocompetent individuals found to have high EBV-DNA load (>1 x 10³ copies/ml) in peripheral blood during physical examination
- Willing to participate in follow-up by telephone or face-to-face interview
You will not qualify if you...
- Diagnosed immunodeficiency
- Taking or planning to take immunosuppressive drugs
- Diagnosed with a validated hematopathy
- Diagnosed with precancerous lesion or malignant tumor with life expectancy less than 1 year
- Psychological illness preventing understanding of the study and voluntary participation
- Pregnant women
- Lack of written informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Five years or more if necessary
Participants with high EBV-DNA load are periodically followed up by telephone or face-to-face interview to track health status and potential development of hematological malignancies.
Periodic telephone or face-to-face interviews
Trial Site Locations
Total: 1 location
1
Tongji hospital, Tongji medical collage of HUST
Wuhan, Hubei, China, 430000
Actively Recruiting
Research Team
J
Jin Huang, PhD.and MD.
J
Jianfeng Zhou, PhD.and MD.
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here